This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.
| Registry number | NCT00148486 |
|---|---|
| Status | Completed |
| Phase | Phase 2 |
| Sponsor | Boehringer Ingelheim |
| Enrollment | 261 participants |
| Design | Interventional, Randomized, Parallel, Masking: Double |
| Conditions | Parkinson Disease |
| Interventions | NS 2330 |
| Start | Jun 2003 |
| Primary completion | Mar 2005 |
| Study completion | Not stated |
| Results posted | Not yet |
| Registry last updated | Oct 29, 2013 |
Compounds on this site that cite this trial
What the registry says the trial is about
To demonstrate efficacy and dose-response of NS 2330 versus placebo in patients with early Parkinson's Disease in 14 weeks of treatment, and to investigate the safety and tolerability of NS 2330 in these patients.
Primary outcomes
These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.
| Outcome measure | Time frame |
|---|---|
| Mean change from Baseline to Week 14 in the score of the UPDRS, Parts I-III combined | baseline and 14 Weeks |
| Proportion of patients who were withdrawn from the study due to AEs | baseline and 14 Weeks |
16 secondary outcomes also registered. See the registry record for the full list.
Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Oct 3, 2026. See the trial changes feed for what has changed recently.
